Dawn Davis MD
Professor of Dermatology and Pediatrics, Mayo Clinic, Rochester, MinnesotaDr. Dawn Davis is a Professor of Dermatology and Pediatrics at Mayo Clinic Rochester. A native of Kansas City, she graduated from the University of Missouri Honors College with a degree in Biology, followed by a Medical Doctorate with honors from the University of Missouri School of Medicine. Dr. Davis is a member of Alpha Omega Alpha. Dr. Davis serves Mayo Clinic as the Enterprise Medical Director of the Referring Provider Office and Alumni Relations. She is a former Mayo Clinic Diversity Leader. Dr. Davis is the founder of the Pediatric Dermatology Fellowship and currently serves as the Division Chair of Clinical Dermatology. She is a frequent spokesperson for Mayo Clinic media relations and writes for MayoClinic.com. She has received the Excellence in Patient Care Award and the Excellence in Clinical Dermatology Award at Mayo Clinic.
Dr. Davis serves Dermatology external to Mayo Clinic. She is a Past President of the Society for Pediatric Dermatology and directed the Annual SPD conference in 2016. She currently serves Dermatology in the SSS of the AMA. Dr. Davis is Co-Chair of the AAD Atopic Dermatitis Guidelines Task Force and a former member of the AAD Psoriasis Guidelines Task Force. She also supports the National Eczema Association Coalition for Better Eczema Care initiative. Locally, she is a Trustee for the Ronald McDonald House in Rochester and has served as President. She is a board member of the Greater Rochester Arts and Cultural Trust. She was inducted into the American Dermatological Association in 2018 and serves as an Associate Editor of Pediatric Dermatology. Dr. Davis actively contributes to the literature and enjoys mentor trainees.
Disclosures
Dr. Davis has no relevant disclosures.Recent Contributions to PracticeUpdate:
- Atopic March Risk in Pediatric Patients With Atopic Dermatitis Prescribed Dupilumab vs Conventional Immunomodulators
- Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma
- Predictors of Severity in Paradoxical Psoriasis Due to Biologic Therapies
- Safety of JAK Inhibitors for Short-term Treatment of Atopic Dermatitis
- Association of Early Life Exposure to Antibiotics With Risk of Atopic Dermatitis